Analysts predict an EPS of $0.05 and revenue of $470.28 million for Symbiotic (NASDAQ:SYM). The company's revenue growth is attributed to the deployment of 39 new systems. Symbiotic faces challenges with a negative P/E ratio of -46.66, but maintains a reasonable liquidity with a current ratio of 1.31. Symbiotic (NASDAQ:SYM) is preparing to announce its quarterly earnings on November 18, 2024. Analysts predict an earnings per share (EPS) of $0.05, with revenue expected to reach $470.28 million. Symbiotic is known for its innovative systems and solutions, and it competes with other tech companies in the industry. The anticipated revenue growth is linked to the deployment of 39 systems, which are currently being implemented. This expansion is expected to positively impact Symbiotic's top-line results, as highlighted by the company's strategic initiatives. Despite this, Symbiotic faces challenges with a negative price-to-earnings (P/E) ratio of -46.66, indicating current negative earnings. Investors are paying attention to Symbiotic's price-to-sales ratio of 1.85, which suggests they are willing to pay $1.85 for every dollar of sales. This ratio provides insight into how the market values the company's sales. Additionally, the enterprise value to sales ratio of 1.34 offers a perspective on the company's valuation relative to its sales. Symbiotic's enterprise value to operating cash flow ratio stands at 26.26, reflecting its valuation in relation to cash flow from operations. This ratio is crucial for understanding how the company is valued based on its ability to generate cash. Despite a negative earnings yield of -2.14%, Symbiotic maintains a current ratio of 1.31, indicating a reasonable level of liquidity to cover short-term liabilities.